Oncotarget

Research Papers:

Development of novel long noncoding RNA MALAT1 near-infrared optical probes for in vivo tumour imaging

Meng-Jie Dong, Cai-Qin Wang, Guo-Lin Wang, Yue-Hong Wang and Zhen-Feng Liu _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:85804-85815. https://doi.org/10.18632/oncotarget.20652

Metrics: PDF 1166 views  |   HTML 2548 views  |   ?  


Abstract

Meng-Jie Dong1,2, Cai-Qin Wang3, Guo-Lin Wang1, Yue-Hong Wang4 and Zhen-Feng Liu1

1The Department of Nuclear Medicine, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, China

2Key Laboratory of Precision Diagnosis and Treatment for Hepatobiliary and Pancreatic Tumor of Zhejiang Province, Hangzhou 310003, China

3Key Laboratory of Reproductive Genetics (Zhejiang University), Ministry of Education, Zhejiang Province, 310003, China

4Department of Respiratory Medicine, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, China

Correspondence to:

Zhen-Feng Liu, email: zhenfeng19792003@zju.edu.cn

Keywords: long noncoding RNA, MALAT1, optical probes, tumour imaging, antisense

Received: June 22, 2017    Accepted: July 26, 2017    Published: September 05, 2017

ABSTRACT

With the advent of next-generation sequencing technology, there is rapidly increasing interest in long noncoding RNAs (lncRNAs). The objectives of this study were to develop a novel lncRNA MALAT1 near-infrared optical probe, to evaluate the characteristics of this optical imaging probe in vitro and to determine whether it can be used for imaging MALAT1 expression in malignant tumours in vivo. Conjugation of Cy5.5 to MALAT1 ASO was accomplished using standard NHS (N-hydroxysuccinimide) ester procedures, and the labelled MALAT1 ASO was purified with a Glen-Pak DNA Purification Cartridge and reversed-phase high performance liquid chromatography (HPLC). The in vitro cellular uptake results showed that the percentage of cell binding increased with an increasing final concentration and increased with increasing incubation time for the MHCC-LM3 tumour cell flow cytometry analyses. in vivo optical imaging exhibited 5’ (Cy5.5)-MALAT1 ASO uptake in the tumour with a maximum at 30 min p.i. that slowly washed out over time. High contrast to normal tissue was gradually observed from 4 h to 48 h p.i. Tumour-to-normal ratios of fluorescence intensities were plotted as a function of time. The in vivo competition assay showed little uptake of the probe into the tumours at any time point, indicating effective competition, selectivity of probe binding and retention by tumours in vivo. Our proposed Cy5.5 labelling of MALAT1 ASO can serve as a potent optical probe for in vivo imaging of tumour expressing MALAT1. Importantly, the successful development of optical probes provides a basis for specific molecular diagnoses in the field of lncRNAs.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 20652